mProX™ Human CIT Stable Cell Line

Sub Cat	Product Name	Target Protein Species	Host Cell Type	Assay Types	Inquiry	Datasheet
S01YF-1122-KX1095	Magic™ Human CRIK(CIT) in Vitro Assay	Human		Kinase Assay

Product Information

Target Protein

CIT

Target Family

Kinases/Enzyme Drug Discovery Assays and Products

Target Protein Species

Human

Host Cell Type

HeLa; CHO-K1; HEK293

Target Classification

Kinase Cell Lines

Target Research Area

Reproductive Research

Related Diseases

Microcephaly 17, Primary, Autosomal Recessive and Primary Autosomal Recessive Microcephaly. Among its related pathways are Signaling by Rho GTPases and RHOC GTPase cycle

Gene ID

11113

UniProt ID

O14578

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

The CIT gene in humans codes for the enzyme citron Rho-interacting kinase. Its overexpression in HeLa cells caused the host cells to become multinucleated, and its removal hinders the preservation of the midbody. Citron-K is expressed during the process of neurogenesis and is involved in the division of neural progenitor cells. In both rats and mice, recessive mutations in Citron-K result in severe microcephaly. Neurogenic cytokinesis abnormalities are caused by loss of Citron-K expression in both humans and animals. Similar to this, RNAi suppression of Citron-K in Drosophila causes cellular abscission to fail. The condition microlissencephaly is linked to CIT. The customized CIT stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat Lisa

The CIT overexpression cell line has played a pivotal role in our journey of discovery. Dec 27 2022

chat Verified Customer

chat Michael

I've used the CIT cell line in multiple assays, and each time, it has exceeded my expectations. Nov 24 2021

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 CIT-K is essential for the completion of cytokinesis in a panel of cancer cell lines.

After plating HeLa Kyoto cells on coverslips, the cells were treated with siRNA for 48, 72, or 96 hours (h) against either CIT-K or a random sequence (control). The cells were then frozen and stained to identify tubulin (green) and DNA (blue).

Ref: McKenzie, Callum, and Pier Paolo D'Avino. "Investigating cytokinesis failure as a strategy in cancer therapy." Oncotarget 7.52 (2016): 87323.

Pubmed: 27895316

DOI: 10.18632/oncotarget.13556

Research Highlights

Before CIT training can be regarded as an evidence-based approach that should be widely used, more research is required. It may be more successful to implement new training protocols that take into account empirical research and are sensitive to the resources available in specific organizations and communities.
Peterson, Jillian, and James Densley. "Is Crisis Intervention Team (CIT) training evidence-based practice? A systematic review." Journal of Crime and Justice 41.5 (2018): 521-534.

A normal 123I-FP-CIT scan does not rule out DLB with just mild brainstem involvement, but an abnormal scan strongly suggests Lewy body disease. This work offers Class I proof that patients with DLB can be reliably identified by 123I-FP-CIT dopaminergic neuroimaging.
Thomas, Alan J., et al. "Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB." Neurology 88.3 (2017): 276-283.
Pubmed: 27940650 DOI: 10.1212/WNL.0000000000003512